|
#
|
Title
|
Authors
|
Affiliations
|
Keywords
|
|
P381
|
The BET bromodomain inhibitor ZEN-3694 modulates the expression of checkpoint receptors and immune suppressive factors in the blood of mCRPC patients
|
Eric Campeau1, Henrik Hansen1, Sanjay Lakhotia2, Karen Norek1, Laura Tsujikawa1, Sarah Attwell1
|
1Zenith Epigenetics, Calgary, AB, Canada 2Zenith Epigenetics, San Francisco, CA, USA
|
Immune monitoring
|
|
P382
|
ATR Inhibition Sequenced with Radiation Therapy Abrogates Immune Exhaustion
|
David Clump1, Christopher Bakkenist1, Frank Vindetti1, Greg Delgoffe2, Robert Ferris1
|
1UPMC Hillman Cancer Center, Pittsburgh, PA, USA 2University of Pittsburgh School of Medicine, Pittsburgh, PA, USA
|
Immune tolerance | Radiotherapy | Tumor infiltrating lymphocytes (TILs) | Regulatory T cell (Treg)
|
|
P383
|
Molecular and immune characterization of melanoma metastases with heterogeneous PTEN expression
|
Mariana Petaccia de Macedo1, Feng Wang2, Diego Marzese3, Courtney Hudgens2, Meredith McKean2, Khalida Wani2, Lauren Haydu2, Patrick Danaher4, Christopher Merritt4, Giang Ong4, Sarah Warren4, Joseph Beechem4, Dave Hoon3, Weiyi Peng2, Lawrence Kwong2, Michael Tetzlaff2, Alexander Lazar2, Michael Davies2
|
1AC Camargo Cancer Center, São Paulo, Brazil 2MD Anderson Cancer Center, Houston, TX, USA 3John Wayne Cancer Institute, Santa Monica, CA, USA 4NanoString Technologies, Seattle, WA, USA
|
Tumor microenvironment | Proteomics | Gene expression | Solid tumors
|
|
P384
|
Mechanisms of efficacy during TGFbR1 inhibition/cytotoxic combination therapy for rectal cancer
|
Andrew Gunderson1, Kayla McCarty1, Michaela Phillips1, Emily Hodel1, Michael Gough1, Marka Crittenden1, Kristina Young1
|
1Earle A. Chiles Cancer Research Institute, Portland, OR, USA
|
Immune tolerance | Chemotherapy | Antigen presenting cells | B cell | Immune suppression | Tumor stroma | Immune monitoring | Tumor microenvironment | Radiotherapy | Targeted therapy
|
|
P385
|
A HSP-TLR-Wnt5a Paracrine Signaling Axis Drives CXCR2 Ligand Recruitment of Myeloid-derived Suppressor Cells and Represents a Novel Adaptive Resistance Mechanism to Anti-PD-1 Antibody Therapy
|
Bala Theivanthiran1, Nicholas C. DeVito1, Kathy Evans1, Fei Zhao1, Christine Xiao1, Benjamin S. Goldschmidt2, Rob Edgar2, Alisha H. Holtzhausen3, April K.S. Salama1, John Lewicki4, John H. Strickler1, John A. Viator2, Brent A. Hanks5
|
1Duke University, Durham, NC, USA 2Duquesne University, Pittsburgh, PA, USA 3University of North Carolina, Chapel Hill, NC, USA 4OncoMed Pharmaceuticals, Inc., Redwood City, CA, USA 5Duke University, Durham, NC, USA
|
Myeloid cells | Tumor microenvironment | TLR | MDSC | Tumor evasion | Checkpoint blockade | T cell | Chemokine
|
|
P386
|
Tracking the dynamic response to vaccine prime/oncolytic boost immunotherapy identifies key mechanisms of immune resistance in metastatic ovarian cancer
|
AJ Robert McGray1, Raya Huang1, Sebastiano Battaglia1, Cheryl Eppolito1, Anthony Miliotto1, Mukund Seshadri1, Kyle Stephenson2, Brian Lichty2, Kunle Odunsi1
|
1Roswell Park Cancer Institute, Buffalo, NY, USA 2McMaster University/Turnstone Biologics, Hamilton & Ottawa, Canada
|
Tumor microenvironment | Gene expression | Immune adjuvant | Immune suppression | Solid tumors | T cell | Tumor infiltrating lymphocytes (TILs) | Vaccine | Tumor evasion | Checkpoint blockade
|
|
P387
|
IFNγ signaling in Tregs acts as a barrier to immunotherapeutic response.
|
Abigail Overacre-Delgoffe1, Maria Chikina1, Rebecca Dadey1, Hiroshi Yano1, Erin Brunazzi1, Gulidanna Shayan2, William Horne1, Jessica Moskovitz2, Jay Kolls1, Cindy Sander2, Yongli Shuai1, Daniel Normolle1, John Kirkwood2, Robert Ferris2, Greg Delgoffe2, Tullia Bruno2, Creg Workman1, Dario Vignali1
|
1University of Pittsburgh, Pittsburgh, PA, USA 2University of Pittsburgh Cancer Institute, Pittsburgh, PA, USA
|
Immune tolerance | Regulatory T cell (Treg) | Tumor microenvironment | Checkpoint blockade | Immune suppression | Tumor infiltrating lymphocytes (TILs)
|
|
P388
|
Neutrophil-Rich Inflammation and PD1/PD-L1 inhibitor Resistance in Advanced Non-Small Cell Lung Cancer Patients
|
Wungki Park1, Sandra Algaze2, Vaia Florou1, Diana Saravia1, Deukwoo Kwon1, Gilberto Lopes1
|
1University of Miami, Miller School of Medicine, Sylvester Comprehensive Cancer Center, Miami, FL, USA 2University of Miami, Miller School of Medicine, Miami, FL, USA
|
Inflammation | Myeloid cells | Checkpoint blockade | Immune monitoring
|
|
P389
|
Aurora kinase inhibition enhances the efficacy of immunotherapy
|
Simone Punt1, Shruti Malu2, Rina Mbofung1, Jodi McKenzie1, Zhe Wang3, Leila Williams1, Jie Qing Chen1, Sourindra Maiti1, Trang Tieu1, Weiyi Peng1, Chengwen Liu1, Chunyu Xu1, Marie-Andrée Forget1, Cara Haymaker1, Jahan Khalili4, Nikunj Satani1, Florian Muller1, Laurence Cooper5, Jason Roszik1, Rodabe Amaria1, Chantale Bernatchez1, Timothy Heffernan1, Patrick Hwu1
|
1The University of Texas MD Anderson Cancer Center, Houston, TX, USA 2The University of Texas MD Anderson Cancer Center (current: Eli Lilly and Company), Indianapolis, IN, USA 3The University of Texas MD Anderson Cancer Center (current: The Journal of Experimental Medicine), New York, NY, USA 4The University of MD Anderson Cancer Center (current: Personal Peptides LLC), Seattle, WA, USA 5The University of Texas MD Anderson Cancer Center (current: Ziopharm Oncology, Inc.), Houston, TX, USA
|
Checkpoint blockade | Targeted therapy | Immune suppression | Tumor infiltrating lymphocytes (TILs) | Adoptive immunotherapy
|
|
P390
|
Combination radiotherapy and αOX40/αCTLA-4 immunotherapy reverses anergy and prevents development of functional exhaustion within tumor-specific CD8 T cells
|
Joshua Walker1, Melissa Kasiewicz2, William Redmond2
|
1Oregon Health & Science University, Portland, OR, USA 2Providence Cancer Center, Portland, OR, USA
|
Costimulation | Immune tolerance | Checkpoint blockade | Radiotherapy | Solid tumors | T cell | Tumor infiltrating lymphocytes (TILs) | Tumor antigens | Cytokine
|
|
P391
|
Non-conventional inhibitory CD4+ Foxp3- PD-1 hi T cells as a biomarker of immune checkpoint blockade activity
|
Roberta Zappasodi1, Sadna Budhu1, Matthew Hellmann1, Michael Postow1, Yasin Senbabaoglu1, Yanyun Li1, Cailian Liu1, Hong Zhong1, Billel Gasmi1, Daniel Hirschhorn-Cymerman1, Katherine Panageas1, Taha Merghoub1, Jedd Wolchok1
|
1MSKCC, New York, NY, USA
|
Biomarkers | Checkpoint blockade | Immune monitoring | Immune suppression | T cell | Tumor evasion
|